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298Objective:Activation of presynaptic voltage-gated calcium channels and release of glutamate play a central role
in neuronal necrosis after cardiopulmonary bypass with deep hypothermic circulatory arrest. Pregabalin binds to
the a2-d subunit of voltage-gated calcium channels resulting in reduced glutamate release. The aim of this study
is to evaluate the effect of pregabalin on cerebral outcome after cardiopulmonary bypass with deep hypothermic
circulatory arrest through an established rat model allowing long-term survival.
Methods: Male Sprague–Dawley rats were randomized to receive intraperitoneal injection of 30 mg/kg of
pregabalin or an equal amount of normal saline 1 hour before cardiopulmonary bypass (n ¼ 10, each).
Rats were cooled to a pericranial temperature of 18C and underwent deep hypothermic circulatory arrest for
60 minutes. Neurologic performance was assessed at postoperative days 3, 7, and 12. Cognitive performance
(Morris water maze) was assessed daily from postoperative day 3 to 12 when histologic assessment was
performed.
Results: Neurologic scores were significantly better in the pregabalin group than in the control group at all
time points of measurements. Morris water maze latencies were not statistically different between the groups.
The percentage of necrotic neurons in the cerebral cortex was significantly less in the pregabalin group
compared with the control group (8.6% [interquartile range, 5.0-8.9] vs 13.6% [interquartile range, 6.9-
18.6], P ¼ .045), whereas no difference was observed in the hippocampus.
Conclusions: Preemptive treatment with pregabalin conveyed a beneficial influence on functional and histologic
cerebral outcome in rats undergoing 60 minutes of deep hypothermic circulatory arrest after cardiopulmonary
bypass without any noticeable side effects. (J Thorac Cardiovasc Surg 2014;148:298-303)Cerebral injury remains a major complication after cardiac
surgery, affecting patients’ outcome and resource use, yet
its prevention proves to be difficult.1 Principal causes
accounting for the postoperative cerebral injury after
cardiopulmonary bypass (CPB) include cerebral emboli,
hypoperfusion, and systemic inflammatory response.2 On
the extreme side of hypoperfusion, deep hypothermic
circulatory arrest (DHCA), a technique intermittently
used for the repair of complex pediatric and adult congenital
cardiac and aortic arch lesions, poses a substantial risk for
cerebral injury, mandating a neuroprotective strategy.3,4
After depletion of adenosine triphosphate (ATP) caused
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channel (VGCC) occurs, resulting in excessive release of
excitatory amino acids, such as glutamate. These events
lead to increased calcium influx to the cell, alterations in
protein kinase activities, and ultimately neuronal cell
death.5,6 Glutamate excitotoxicity persists for hours after
reperfusion, which continues to trigger these complex and
interrelated biochemical events leading to neuronal cell
death.7
Pregabalin, which has been widely used to control
neuropathic pain, potently binds to the a2-d subunit of
VGCC.8 Its binding at this site reduces calcium influx at
presynaptic nerve endings, resulting in reduced release
of glutamate and noradrenalin, an action mechanism
expected to protect neurons from ischemia/reperfusion
injury. Indeed, pregabalin exerted anti-apoptotic and
anti-inflammatory effects accompanied by improved
functional outcome in a rat model of spinal cord injury.9
It also showed promising results in a mouse model of
middle cerebral artery occlusion in terms of reduction in
neuronal loss.10 Despite this theoretic background,
evidence regarding pregabalin’s influence on cerebral
outcome in a cardiac surgical setting using CPB is lacking.
The aim of this study was to validate the influence of
preemptive administration of pregabalin on functional
(cognitive and neurologic) and histologic cerebral outcomeery c July 2014
Abbreviations and Acronyms
ATP ¼ adenosine triphosphate
CPB ¼ cardiopulmonary bypass
DHCA ¼ deep hypothermic circulatory arrest
IQR ¼ interquartile range
MAP ¼ mean arterial pressure
NMDA ¼ N-methyl-D-aspartate
POD ¼ postoperative day
VGCC ¼ voltage-gated calcium channel
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Musing a clinically relevant rat model of CPBwith 60minutes
of DHCA.11
METHODS
Animals and Drug Treatment
This study was approved by the Duke University Institutional Animal
Care and Use Committee, and all procedures met the National Institutes
of Health guidelines for animal care (Guide for the Care and Use of
Laboratory Animals, available at: www.nap.edu/catalog/5140.html).
Twenty male Sprague–Dawley rats (age, 14-16 weeks; weight, 400-450
g; Charles River Laboratories, Inc, Wilmington, Mass) were studied.
Animals were randomly allocated to receive 2mL of 0.9% sodium chloride
solution intraperitoneally with (pregabalin group, n ¼ 10) or without
(control group, n ¼ 10) pregabalin 30 mg/kg, after anesthetic induction
at 60 minutes before the commencement of CPB. Pregabalin was
graciously provided free of charge through a compound transfer program
by Pfizer Inc., New York, NY.
Cardiopulmonary Bypass and Deep Hypothermic
Circulatory Arrest
Fasted rats were anesthetized for 5 minutes with 5% isoflurane in
oxygen in a transparent induction box. After anesthetic induction, the
trachea was intubated and the lungs were mechanically ventilated with a
tidal volume of 10 mL/kg and respiratory rate of 60 to 65 beats/min to
maintain the arterial carbon dioxide tension between 35 and 45 mm Hg
(Harvard Rodent Respirator, Harvard Apparatus, Boston, Mass). During
surgery, anesthesia was maintained with 2.0% to 2.5% isoflurane and
fentanyl (25 mg/kg, intravenous, as a bolus injection).
Animalswere prepared for CPB as previously reported.11 Briefly, the tail
artery was cannulated for aortic inflow, amultistaged venous return cannula
was placed near the junction of the inferior vena cava and right atrium
through the right external jugular vein, and the right superficial caudal
epigastric artery was cannulated for monitoring (model 90603A, Space-
Labs, Inc, Redmond,Wash)mean arterial pressure (MAP). After the cannu-
lation of the tail artery and jugular vein, animals received 150 units of
heparin. During CPB, anesthesia was maintained using 0.5% to 1.2% iso-
flurane and fentanyl (intravenous, 150 mg/kg). No paralytics were adminis-
tered until just before CPB when pancuronium (0.1 mg/kg) was
administered to prevent spontaneous breathing during CPB. Fentanyl and
pancuronium were repeated (at half the dose) at 30-minute intervals, as
necessary. Pericranial temperature was monitored with CSC 32 (OMEGA
Engineering, Inc, Stamford, Conn). The CPB circuit consisted of a venous
reservoir, a peristaltic pump (Tygon;Cole-Parmer Instrument,VernonHills,
Ill), a membrane oxygenator, and an arterial inflow cannula. An in-line flow
probe (2N806 flow probe and T208 volume flowmeter; Transonic Systems,
Inc, Ithaca, NY) was used to continuously measure CPB flow. The bypass
circuit was primed with approximately 8 mL of 6% hydroxyethyl starch
130/0.4. One hundred units of heparin were added to the prime. Arterial
blood gases were analyzed using a GEM Premier 3000 blood gas/The Journal of Thoracic and Caelectrolytic analyzer (model 5700, Instrument Laboratories, Inc, Lexington,
Mass). Basic physiologic data, including MAP, temperature, and blood
gases, were collected 15 minutes before commencement of CPB, 10 mi-
nutes before DHCA, 10minutes beforeweaning from CPB, and 15minutes
and 2 hours after weaning from CPB.
CPB was commenced at a flow rate of 160 to 180 mL/min/kg and then
decreased during the cooling period of 30 minutes to a target pericranial
temperature of 18C. After reaching 18C, the rats were subjected to
DHCA confirmed by the presence of asystole and the absence of any
measurable MAP, while carefully draining the venous blood to a reservoir.
After 60minutes of DHCA, CPBwas reinstituted and the rats werewarmed
to a pericranial temperature of 34C for 30 minutes while gradually
increasing the flow rate to 160 to 180mL/min/kg.Then the ratswereweaned
from CPB, and heparin-induced anticoagulation was allowed to dissipate
spontaneously without protamine. After decannulation, rats were main-
tained anesthetizedwith 0.5% to 1.2% isoflurane, intubated, and ventilated
for 2 hours while warming the rats to a pericranial temperature of 36C to
37C.When adequate spontaneous breathing resumed, the animalswere ex-
tubated and recovered in an oxygen-enriched box for 24 hours with free ac-
cess to water and food. During the first 6 hours of recovery, they were
continuously observed to identify signs of immediate cerebral death and se-
vere neurologic dysfunction (fixed pupils, absence of spontaneous breath-
ing, seizures, and inability to ambulate). Animals demonstrating signs of
severe neurologic dysfunction were killed (2 rats in the control group and
1 rat in the pregabalin group died 1 day after DHCA. These rats were re-
placedwith new rats). All other rats were returned to their cages and housed
individually. All animals were supported for 12 days postoperatively for
neurologic and neurocognitive testing. On the 12th postoperative day
(POD), animals were killed for histologic evaluation.
Neurologic and Neurocognitive Testing
On the 3rd, 7th, and 12th PODs, animals underwent standardized
functional neurologic testing using an established neurologic scoring
system that evaluates 4 different functions: general status, simple motor
deficit, complex motor deficit, and sensory deficit.12 The score given to
each animal at the completion of the testing (by an observer blinded to
group assignment) was the sum of all 4 individual scores: 0 was the
minimum (best) score, and 48 was the maximum (worst) score.
In addition to the neurologic evaluation, neurocognitive outcome was
evaluated daily (starting on the third POD) in the Morris water maze using
a computerized video tracking system (EthoVision; Noldus, Wageningen,
The Netherlands).13 TheMorris water maze consisted of a 1.5-m–diameter,
30-cm–deep pool of water (27C) with a hidden submerged (3 cm below
the surface) platform in 1 quadrant. Rats were placed in thewater in a dimly
lit room. The time to locate the submerged platform (defined as the latency)
was measured to test for impairment in visuospatial learning and memory
components of neurocognition. Rats underwent daily testing in the water
maze with 4 trials per testing period, each limited to 90 seconds of water
exposure. Each of the trials was begun from a separate quadrant. Testing
was performed for 10 consecutive days until the 12th POD.Histologic Examination
After completion of the testing on the final day (12th POD),
animals were anesthetized with isoflurane and perfusion-fixed in situ by
intracardiac infusion of buffered 4% paraformaldehyde solution. After
brain were embedded in paraffin, they were sliced at 5 mm in thickness.
Necrotic cell death was identified by acid fuchsin-celestine blue and
quantified by counting necrotic neurons in 5 representative areas of the
cortex and the CA1 section of the hippocampus at 403 magnification.Statistics
Statistical analyses were performed using SAS version 9.2 (SAS Institute,
Inc,Cary,NC).All dataare expressedasmean standarddeviationormedianrdiovascular Surgery c Volume 148, Number 1 299
TABLE 1. Operative data
Pre-CPB
CPB Post-CPB
Cooling 20 min Warming 20 min 15 min 2 h
SMAP (mm Hg)
Control 70  5 44  10 44  4 70  9 74  6
Pregabalin 71  5 40  6 44  3 71  11 72  5
Temperature (C)
Control 33.6  0.3 20.9  1.4 28.5  1.2 34.2  0.7 36.1  0.3
Pregabalin 33.9  0.3 21.7  1.0 27.9  0.9 34.2  0.7 36.0  0.3
pH
Control 7.42  0.06 7.46  0.04 7.43  0.03 7.39  0.06 7.44  0.04
Pregabalin 7.42  0.08 7.46  0.04 7.46  0.05 7.35  0.07 7.41  0.08
PaO2 (mm Hg)
Control 193  65 482  131 319  95 115  31 367  91
Pregabalin 258  99 549  125 375  107 96  20 307  101
PaCO2 (mm Hg)
Control 45  7 38  4 33  3 45  6 40  7
Pregabalin 46  11 40  5 31  4 50  10 45  11
Hemoglobin (mg/dL)
Control 13.3  0.7 7.9  0.7 8.6  0.5 9.1  0.7 11.8  1.0
Pregabalin 12.8  0.8 7.6  0.4 8.5  0.5 9.3  0.9 11.3  0.6
Glucose (mg/dL)
Control 103  16 183  28 149  26
Pregabalin 106  14 177  36 141  35
Data are presented as mean  standard deviation. N¼ 10 in each group. All P values are>.05 in intergroup comparisons. CPB, Cardiopulmonary bypass; PaCO2, arterial carbon
dioxide tension; PaO2, arterial oxygen tension; SMAP, systemic mean arterial pressure.
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M(interquartile range). For continuous variables, intergroup comparisons were
performed by independent t test or Mann–WhitneyU test as appropriate. For
continuous variables measured at multiple time points, repeated measures of
analysis of variance or Mann–Whitney U test was used as appropriate with
Bonferroni correction of the resulting P values. Neurologic scores were
analyzed using the Mann–Whitney U test with Bonferroni correction of the
resulting P values. All statistical tests were 2-tailed.TABLE 2. Morris water maze test
P valueRESULTS
Operative Data
Physiologic parameters of the rats, including pericranial
temperature, MAP, flow rate, and blood gas analysis
variables, were all similar between the groups at each
aforementioned time point (Table 1).Control
(n ¼ 10)
Pregabalin
(n ¼ 10) Intergroup
Intragroup
Control Pregabalin
Latency (sec)
POD 3 263  76 223  76 .252
POD 4 188  99 121  57 .078 .899 <.001
POD 5 151  88 88  51 .064 .027 <.001
POD 6 141  96 74  49 .065 .010 <.001
POD 7 108  89 64  30 .160 <.001 <.001
POD 8 54  41 46  24 .603 <.001 <.001
POD 9 64  45 35  12 .081 <.001 <.001
POD 10 64  72 34  10 .196 <.001 <.001
POD 11 44  24 38  16 .510 <.001 <.001
POD 12 47  16 41  18 .398 <.001 <.001
Data are expressed as mean  standard deviation. Intergroup comparisons
were performed using independent t test with Bonferroni correction. Intragroup
comparisons were performed using repeated measures of analysis of variance
followed by post hoc Dunnett’s test. POD, Postoperative day.Neurologic and Neurocognitive Testing
Neurologic scores assessed at the 3rd (3.0 [Interquartile
range {IQR}, 1.0-4.5] vs 12.5 [IQR, 8.3-15.3], P ¼ .002),
7th (2.0 [IQR, 0.0-2.3] vs 9.5 [IQR, 6.8-12.8], P< .001),
and 12th (1.0 [IQR, 0.0-2.0] vs 9.0 [IQR, 5.3-12.3],
P<.001) PODs were all significantly better in the pregaba-
lin group compared with the control group.
The results of the water maze latencies denoting the
cumulative time taken by animals to find the platform on
the basis of the 4 trials of each day are shown in Table 2.
In intergroup comparisons of the latencies, there were no
statistically significant differences between the groups.
Only trends were observed toward shorter latencies in the
pregabalin group on the 4th, 5th, 6th, and 8th PODs300 The Journal of Thoracic and Cardiovascular Surgcompared with the control group. In intragroup
comparisons of the latencies compared with each baseline
value at the 3rd POD, significant improvement was
observed from the 4th and 5th POD onward in the
pregabalin and control groups, respectively.
Histologic Examination
The percentage of necrotic neurons in the CA1 section of
the hippocampus was lower in the pregabalin group
compared with the control group (2.8% [IQR, 1.9-3.2] vsery c July 2014
FIGURE 1. Necrotic neurons identified by acid fuchsin-celestine blue in
representative brain sections (arrows, original magnification 403) from
rats treated with pregabalin (30 mg/kg) or saline (control) intraperitoneally
1 hour before the commencement of CPB.
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M4.1% [IQR, 2.8-12.4], P¼ .185), but without statistical sig-
nificance. The percentage of necrotic neurons in the cere-
bral cortex was significantly lower in the pregabalin group
compared with the control group (8.6% [IQR, 5.0-8.9] vs
13.6% [IQR, 6.9-18.6], P ¼ .045) (Figure 1).
DISCUSSION
Preemptive treatment with pregabalin before CPB
significantly attenuated the degree of ensuing cerebral
injury as evidenced by significantly reduced cerebral
cortical neuronal loss and better neurologic scores in rats
after 60 minutes of DHCA.
From cognitive dysfunction to overt stroke, cerebral
injury after cardiac surgery exerts considerable influence
on patients’ outcomes and medico-social resource use.1
Although diverse factors, including the patient’s comorbid
diseases, are thought to be involved, primary and universal
inciting factors of cerebral injury are related to CPB, which
include cerebral emboli and hypoperfusion along with
systemic inflammatory response.2 DHCA provides a
bloodless surgical field without the hindrance of vascular
clamps or cannulae, and continues to be intermittently
used for surgical repair and reoperations of complex
congenital cardiac and aortic arch lesions. DHCA is an
extreme variant of cerebral hypoperfusion, and reported
incidences of cerebral injury after CPB with DHCA are
up to 15% even with a mean duration of 15 minutes.3,4
Thus, neuroprotective strategies should be a high priority
in the perioperative management of these patients, yet
they prove to be difficult.
At the cellular level, the neuropathologic hallmark of
DHCA-induced cerebral injury is neuronal cell death.6,14The Journal of Thoracic and CaDuring cerebral ischemia, depletion of ATP causes failure
of the Na-K-ATPase pump, resulting in depolarization of
presynaptic neurons. Consequently, activation of VGCC
occurs, resulting in calcium influx and excessive release of
glutamate, which leads to further increase in intracellular
calcium and activation of complex-interrelated biochemical
processes resulting in neuronal cell death by necrosis or
apoptosis.5,6 Of interest, glutamate excitotoxicity persists
for hours after reperfusion, continuously triggering
successive biochemical events, which result in additional
neuronal cell death.7
A vast amount of evidence exists regarding the beneficial
influence of agents interrupting a certain ischemia/
reperfusion-induced biochemical event on neuronal cell
death, mostly in focal ischemia models.15,16 These include
the use of glutamate receptor antagonists and VGCC
antagonists as well, both of which showed promising results
in animal studies. However, the results of clinical studies
addressing these neuroprotective agents are disappointing
for various reasons, including an unrealistic therapeutic
window in the clinical setting or the occurrence of serious
side effects.17-19
Pregabalin is a VGCC antagonist that is widely used to
control neuropathic pain in current medical practice.8 Its
binding to an a2-d subunit of VGCC results in reduced
calcium influx in the presynaptic nerve endings,
subsequently leading to reduced release of excitotoxic
substances, an action mechanism expected to reduce
neuronal cell death. Moreover, pregabalin possesses a
highly predictable pharmacokinetic profile and is reported
to have no serious side effects when used in the surgical
setting.8,20,21 In terms of pregabalin’s neuroprotective
effects, pregabalin has been shown to improve the
functional outcome in a rat model of spinal cord injury
via anti-apoptotic and anti-inflammatory effects.9 Pregaba-
lin also has been shown to reduce neuronal loss in a mouse
model of middle cerebral artery occlusion via attenuation of
apoptosis.10 Despite this theoretic background, pregabalin’s
efficacy and safety regarding its possible neuroprotective
effect in the setting of CPB with DHCA have not been vali-
dated heretofore.
As our results indicate, preemptive administration of
pregabalin significantly reduced the neurologic deficit
and the neuronal loss in the cerebral cortex after CPB
with 60 minutes of DHCA.
As in stroke models, discordances between animal
studies and clinical studies persist in the cardiac surgical
setting.22 Preemptive administration of an N-methyl-
D-aspartate (NMDA) receptor antagonist, remacemide,
in patients undergoing coronary artery bypass surgery
conveyed only limited neuroprotection in terms of
neuropsychologic performance.23 Clinically, the use of
glutamate receptor antagonists is complicated by their
own neuropsychotic side effects.18 Moreover, glutamaterdiovascular Surgery c Volume 148, Number 1 301
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Macts not only on NMDA receptors but also on kainate and
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep-
tors, which also participate in the biochemical cascade
leading to neuronal cell death.16 Also, excessive release
of other excitotoxic substances in addition to glutamate
by ischemic discharges of presynaptic neurons may limit
the clinical efficacy of glutamate receptor antagonists.
Unlike glutamate receptor antagonists, pregabalin exhibits
an excellent safety profile and acts more on the upstream
of the cascade, suppressing the calcium influx into
presynaptic terminals, reducing not only the release of
glutamate but also other excitotoxic substances, such as
noradrenaline, an action mechanism overcoming most of
the mentioned pitfalls of NMDA receptor antagonists.
In terms of neurocognitive function and neuronal loss in
the hippocampus, we observed trends toward shorter water
maze latencies and a lower percentage of necrotic neurons,
lacking statistical significance. These findings may be
attributable to the facts that hippocampal neurons are
most vulnerable to ischemia/reperfusion injury, and
neurocognitive dysfunction is closely related to the limbic
system.24Study Limitations
Although selective neuronal necrosis of various regions
is the neuropathologic hallmark of DHCA-induced cere-
bral injury and the current study clearly demonstrates
pregabalin’s neuroprotective effect in that regard,5
neuronal apoptosis has been shown to be an additional
cause of cerebral injury after DHCA.14 Considering that
VGCC activation and excessive release of excitotoxic
substances also induce neuronal apoptosis, distinction of
the type of neuronal cell death (necrosis vs apoptosis)
would have provided a more definite clue regarding the
future application of pregabalin as a neuroprotectant in
the cardiac surgical setting. The rat model of 60 minutes
of DHCA was chosen in this study because it enables
proper assessment of a potentially existing neuroprotec-
tive strategy on cerebral outcome because it has been
shown to result in detectable cerebral injury while allow-
ing long-term survival.11 However, DHCA of 60 minutes
is rarely used in current cardiothoracic surgical practice,
and other patient-related nonmodifiable factors may play
a more significant role in cerebral outcome after short du-
rations of DHCA, limiting the clinical relevance of this
model.25CONCLUSIONS
This study provides primary evidence regarding the
preemptive use of pregabalin’s efficacy and safety on
attenuating the ensuing neurologic deficit and neuronal
loss after CPB with DHCA in rats. Considering the clinical
safety and the highly predictable pharmacokinetic profile of302 The Journal of Thoracic and Cardiovascular Surgpregabalin, further clinical studies are warranted to
validate pregabalin’s neuroprotective efficacy in patients
undergoing cardiac surgery using CPB or DHCA.References
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